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Outcomes Associated With a Strategy of Adjuvant Metolazone or
High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A
Propensity Analysis
Meredith A. Brisco-Bacik, MD, MSCE; Jozine M. ter Maaten, MD; Steven R. Houser, PhD; Natasha A. Vedage, MD; Veena Rao, PhD;
Tariq Ahmad, MD, MPH; F. Perry Wilson, MD, MSCE; Jeffrey M. Testani, MD, MTR
Background-—In acute decompensated heart failure, guidelines recommend increasing loop diuretic dose or adding a thiazide
diuretic when diuresis is inadequate. We set out to determine the adverse events associated with a diuretic strategy relying on
metolazone or high-dose loop diuretics.
Methods and Results-—Patients admitted to 3 hospitals using a common electronic medical record with a heart failure discharge
diagnosis who received intravenous loop diuretics were studied in a propensity-adjusted analysis of all-cause mortality. Secondary
outcomes included hyponatremia (sodium <135 mEq/L), hypokalemia (potassium <3.5 mEq/L) and worsening renal function (a
≥20% decrease in estimated glomerular ﬁltration rate). Of 13 898 admissions, 1048 (7.5%) used adjuvant metolazone.
Metolazone was strongly associated with hyponatremia, hypokalemia, and worsening renal function (P<0.0001 for all) with
minimal effect attenuation following covariate and propensity adjustment. Metolazone remained associated with increased
mortality after multivariate and propensity adjustment (hazard ratio=1.20, 95% conﬁdence interval 1.04–1.39, P=0.01). High-dose
loop diuretics were associated with hypokalemia and hyponatremia (P<0.002) but only worsening renal function retained
signiﬁcance (P<0.001) after propensity adjustment. High-dose loop diuretics were not associated with reduced survival after
multivariate and propensity adjustment (hazard ratio=0.97 per 100 mg of IV furosemide, 95% conﬁdence interval 0.90–1.06,
P=0.52).
Conclusions-—During acute decompensated heart failure, metolazone was independently associated with hypokalemia,
hyponatremia, worsening renal function and increased mortality after controlling for the propensity to receive metolazone and
baseline characteristics. However, under the same experimental conditions, high-dose loop diuretics were not associated with
hypokalemia, hyponatremia, or reduced survival. The current ﬁndings suggest that until randomized control trial data prove
otherwise, uptitration of loop diuretics may be a preferred strategy over routine early addition of thiazide type diuretics when
diuresis is inadequate. ( J Am Heart Assoc. 2018;7:e009149. DOI: 10.1161/JAHA.118.009149.)
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T he primary therapeutic objective in the majority of acutedecompensated heart failure (ADHF) hospitalizations is
relief of congestion.1,2 Intravenous loop diuretics form the
mainstay of decongestive therapy, but unfortunately,
resistance to these agents is common.3 Both US and European
Heart Failure (HF) guidelines state that when diuresis remains
inadequate with loop diuretic therapy, either escalation of loop
diuretic dose or the addition of a thiazide diuretic may be
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considered to intensify the regimen, yet these recommenda-
tion are based on limited data to support the relative safety of
each appraoch.4–6 Notably, sequential nephron blockade
further limits the ability of the kidney to regulate ﬂuid and
electrolyte excretion beyond loop diuretic monotherapy,
potentially leading to complications such as hyponatremia,
hypokalemia, and worsening renal function (WRF).7–10
In the current analysis we set out to better understand the
relationship between the use of the thiazide-type diuretic
metolazone, high-dose loop diuretics (HDLDs), and adverse
outcomes during and after ADHF therapy. The ideal study
design would involve a randomized controlled trial of meto-
lazone powered for all-cause mortality, but unfortunately such
a trial is unlikely to be performed for the foreseeable future.
Therefore, our approach was to use epidemiologic methods
known to reduce confounding by indication, such as propen-
sity score adjustment, to examine the above associations.
Notably, these methods have been previously shown to
eliminate the relationship between HDLDs and inferior
outcomes, thus providing a positive control to the method-
ology while directly evaluating the alternative approach of
high-dose loop diuretic use.11
Methods
This is a propensity-adjusted cohort study of all patients
admitted to 3 independent hospitals that all used a common
electronic medical record within the Yale Health System (Yale
New Haven Hospital, The Hospital of Saint Raphael and
Bridgeport Hospital) between January 1, 2013 and September
30, 2015 whose discharge record included documentation of
congestive heart failure by International Classiﬁcation of
Diseases, Ninth or Tenth Revision (ICD-9 or ICD-10) code.
Inclusion required receiving intravenous loop diuretics within
the ﬁrst 7 days and at least 2 creatinine measurements
during the admission. In the event of multiple hospitalizations
for a single patient, all admissions meeting the inclusion
criteria were maintained, particularly given that patients with
many readmissions are more likely to receive more aggressive
diuretic therapy. Patients without information on race (n=125)
to calculate an estimated glomerular ﬁltration rate (eGFR)
were excluded resulting in a total of 13 898 unique admis-
sions in 8908 patients.
The Chronic Kidney Disease Epidemiology Collaboration
equation was used to calculate eGFR.12 WRF was deﬁned as a
≥20% decrease in eGFR from admission to discharge.13–15 Any
WRF was deﬁned as a ≥20% decrease in estimated glomerular
ﬁltration rate from admission to the point of worst eGFR during
the hospitalization. Hyponatremia was deﬁned as any sodium
level <135 mEq/L and hypokalemia was deﬁned as any serum
potassium <3.5 mEq/L. New hyponatremia was deﬁned as a
sodium level <135 mEq/L and new hypokalemia was deﬁned
as a serum potassium <3.5 mEq/L that developed during the
course of the hospitalization (ie, patients with new electrolyte
abnormalities who did not meet these criteria at admission).
Loop diuretic doses were converted to intravenous furosemide
equivalents with 1 mg bumetanide=20 mg torsemide=40 mg
furosemide.16,17 Peak diuretic dose was deﬁned as the highest
single intravenous (IV) dose of diuretic during the ﬁrst 7 days of
the hospitalization in IV furosemide equivalents. HDLD use was
deﬁned as a peak diuretic dose of >160 mg of IV furosemide
equivalents.18 The Elixhauser Comorbidity Index, a marker of
in-hospital mortality, was determined based on ICD-9 and ICD-
10 diagnostic codes for 30 comorbid conditions.19 All-cause
mortality was determined using the National Death Index.20
This study was approved by the Yale University Institutional
Review Board and informed consent was waived. The data,
analytic methods, and study materials will not be made
available to other researchers for purposes of reproducing the
results or replicating the procedure.
Propensity Score Development
In this population, combination diuretic therapy using meto-
lazone was at the discretion of the treating physician and
therefore the relationship between metolazone and mortality
Clinical Perspective
What Is New?
• In this analysis of nearly 14 000 acute decompensated
heart failure admissions to 3 hospitals with a common
medical record we utilized propensity score adjustment, an
epidemiologic method known to reduce confounding by
indication, to examine the relationship between both
escalating doses of loop diuretics and metolazone with
short-term outcomes and all-cause mortality.
• Notably, the generalizable statistical methodology of
propensity scores utilized in this study successfully adjusted
away the initial perceived mortality disadvantage associated
with increasing doses of loop diuretics, ultimately revealing
their safety, even at higher doses
• However, propensity adjusted analyses of metolazone use
revealed a persistent and signiﬁcant association with
increased mortality, an effect predominantly mediated
through short-term side effects associated with metolazone
including hyponatremia, hypokalemia and worsening renal
function.
What Are the Clinical Implications?
• In the ﬁrst propensity-adjusted and large analysis of
metolazone use in acute decompensated heart failure, this
study strongly calls into question the routine early use of
adjuvant metolazone for treatment of acute decompensated
heart failure when loop diuretic doses have not yet been
optimized.
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Table 1. Baseline Characteristics of All Admissions and Those With and Without Metolazone Use
Characteristic
All Admissions Metolazone Use During Admission
P ValueN=13 898 No (n=12 850) Yes (n=1048)
Demographics
Age at encounter, y 75.014.4 75.414.3 69.914.3 <0.001*
Male sex, % 48.4 47.7 57.5 <0.001*
Black race, % 16.9 16.9 18.2 0.232
Comorbidities
Arrhythmia, % 63.5 62.5 75.1 <0.001*
Valvular disease, % 35.9 35.1 45.2 <0.001*
Pulmonary circulatory disease, % 25.1 24.3 35.1 <0.001*
Peripheral vascular disease, % 13.9 13.9 13.7 0.830
Hypertension without complications, % 42.4 44.2 20.2 <0.001*
Hypertension with complications, % 38.3 36.5 60.1 <0.001*
End-stage renal disease, % 3.89 3.36 10.3 <0.001*
Renal failure, % 39.8 37.7 66.2 <0.001*
Fluid and electrolyte disorders, % 42.0 40.6 59.4 <0.001*
COPD, % 52.5 52.2 56.2 0.012*
Diabetes mellitus without complications, % 31.3 31.1 34.5 0.020*
Diabetes mellitus with complications, % 11.3 10.7 19.5 <0.001*
Hypothyroidism, % 20.6 20.4 22.8 0.063
Obesity, % 21.4 20.6 31.7 <0.001*
Liver disease, % 6.55 6.12 11.8 <0.001*
Peptic ulcer disease, % 0.72 0.71 0.86 0.579
HIV, % 0.41 0.40 0.48 0.724
Lymphoma, % 2.06 1.98 2.96 0.033*
Solid tumor without metastasis, % 5.55 5.73 3.34 0.001*
Metastatic cancer, % 2.67 2.78 1.34 0.005*
Rheumatologic disease, % 4.94 5.07 3.44 0.019*
Coagulopathy, % 6.32 6.11 8.97 <0.001*
Anemia because of blood loss, % 1.92 1.98 1.15 0.057
Anemia because of deficiency, % 6.20 6.16 6.77 0.424
Alcohol abuse, % 4.51 4.54 4.20 0.612
Drug use, % 4.28 4.37 3.15 0.060
Psychoses, % 1.96 1.98 1.62 0.416
Depression, % 16.5 16.4 17.6 0.344
Neurologic disease, % 8.34 8.47 6.77 0.057
Paralysis, % 1.27 1.24 0.38 0.004*
Elixhauser comorbidity index 6.22 6.12 7.22 <0.001*
Diuretics
First dose of diuretic on admission
in intravenous furosemide equivalents, mg
40 (20,40) 40 (20,40) 60 (40,80) <0.001*
Metolazone given on prior admit, % 4.32 2.92 21.5 <0.001*
Continued
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may be confounded by patient factors related to mortality that
also affect the decision to use metolazone. A propensity score
represents the probability that an individual will receive a
given treatment (ie, metolazone) conditional on a set of
baseline characteristics. Propensity score adjustment signif-
icantly reduces treatment selection bias helping to approxi-
mate a randomized controlled trial in the setting of
observational data.21 A propensity score was determined
using multivariable logistic regression with metolazone use as
the dependent variable. Independent variables were com-
prised of patient and admission characteristics that were
associated with metolazone use at a P≤0.2 (Table 1) with no
additional selection procedures. The 39 independent variables
included in the propensity score were age, sex, creatinine,
eGFR, blood urea nitrogen, ﬁrst dose of intravenous diuretic
on admission, prior admission with metolazone use, additional
admission laboratory data (sodium, chloride, bicarbonate,
white blood cell count, hemoglobin, platelet count), arrhyth-
mia, valvular disease, pulmonary circulatory disease, hyper-
tension with and without complications, end-stage renal
disease, renal failure, ﬂuid and electrolyte disorders, chronic
obstructive pulmonary disease, diabetes mellitus, hypothy-
roidism, obesity, liver disease, Elixhauser comorbidity index,
hospital of admission and history of prior admission,
lymphoma, solid tumor without metastasis, metastatic cancer,
rheumatologic disease, coagulopathy, anemia because of
blood loss, drug use, neurologic disease, and paralysis. The
logistic regression was used to determine the probability of
receiving metolazone for each admission, ie, the propensity
score, and is presented in Table S1. The adequacy of the
propensity score in adjusting for metolazone use was
examined by testing for differences in individual covariates
between patients who did and did not receive metolazone
after stratifying by blocks of the propensity score. The
included covariates were well balanced across the metolazone
and no metolazone groups within blocks of the propensity
score. The propensity score successfully adjusted for major
covariates of interest that were found to be highly statistically
signiﬁcantly different between the metolazone groups before
adjustment.22 Given that uptitration of loop diuretics is the
alternate guideline recommended therapy when lower doses
are not effective, as a secondary analysis, a second propen-
sity score was developed using multivariable logistic regres-
sion with high-dose loop diuretic use as the dependent
variable. This propensity model was developed similarly to
that for metolazone and included the following covariates:
metolazone use, baseline diuretic dose, age, arrhythmias,
valvular disease, pulmonary circulatory disease, diabetes
Table 1. Continued
Characteristic
All Admissions Metolazone Use During Admission
P ValueN=13 898 No (n=12 850) Yes (n=1048)
Baseline laboratory values
Sodium, mEq/L 138.04.9 138.14.9 136.95.0 <0.001*
Potassium, mEq/L 4.30.7 4.30.7 4.30.83 0.453
Chloride, mEq/L 100.65.9 100.85.8 98.296.4 <0.001*
Bicarbonate, mEq/L 24.55.0 24.45.0 24.75.2 0.171
Blood urea nitrogen, mg/dL 33.422.5 32.021.1 51.230.8 <0.001*
Creatinine, mg/dL 1.601.4 1.551.3 2.201.5 <0.001*
eGFR, mL/min per 1.73 m2 53.327 54.327 41.128 <0.001*
Glucose, mg/dL 149.777.3 149.777.5 150.474.2 0.762
White blood cell count, K/mm3 10.36.9 10.37.1 9.55.0 <0.001*
Hemoglobin, g/dL 11.62.3 11.62.3 11.02.2 <0.001*
Platelet count, K/mm3 231.4102 232.4102 219.894.0 <0.001*
Hospitalization
Hospital
Yale New Haven Hospital, % 50.5 49.2 66.9 <0.001*
Saint Raphael Campus, % 30.2 31.0 19.7
Bridgeport Hospital, % 19.3 19.8 13.5
Readmission, % 35.9 34.6 51.7 <0.001*
Values reported are meanSD, median (quartile 1 to quartile 3), and percentile. COPD indicates chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate.
*Signiﬁcant P-value.
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mellitus, hypertension, obesity, liver disease, lymphoma,
malignancy, rheumatoid disease, electrolyte disease, coagu-
lopathy, hospital, readmission, Elixhauser comorbidity index
and baseline sodium, chloride, blood urea nitrogen, eGFR,
creatinine, white blood cell count, and platelets. This score
was also well balanced across high- and low-dose diuretic
groups.
Statistical Analysis
Values reported are meanSD, median (quartile 1 to quartile
3), and percentile. The independent Student t test or the
Wilcoxon rank-sum test was used to compare continuous
parameters. The Pearson chi-square was used to evaluate
categorical variables. The primary goal of this analysis was to
evaluate the association between metolazone use during the
treatment of ADHF and all-cause mortality using propensity
score adjustment. Time-varying Cox proportional hazards
modeling was used to evaluate time-to-event associations
with all-cause mortality and to account for multiple admis-
sions per patient. Candidate covariates for multivariable
modeling were obtained by screening all baseline variables,
and those with a univariate association with mortality at
P≤0.2 were entered and retained in the model. Given that in-
patient loop diuretic requirement is strongly related to both
metolazone use and outcomes, and that such information is
not available at baseline, all adjusted analyses included
adjustment for BOTH the propensity score (which includes the
ﬁrst dose of intravenous diuretic in the hospital) and the peak
diuretic dose received in the hospital as a representation of
loop diuretic requirement. A secondary goal of this analysis
was to examine the relationship between metolazone and
other relevant outcomes in ADHF including hyponatremia,
hypokalemia, and WRF. Logistic and linear regression models
were developed and clustered on the individual patient to
account for multiple admissions in the same subject.
Table 2. In-Hospital Characteristics of All Admissions by Metolazone Use
Characteristic
All Admissions Metolazone Use During Admission P Value
N=13 898 No (n=12 850) Yes (n=1048)
Diuretics
Peak diuretic dose during hospitalization in IV furosemide equivalents, mg 80 (40,80) 80 (40,80) 120 (80 160) <0.001*
Last IV diuretic dose before discharge in IV furosemide equivalents, mg 60 (40,80) 40 (40,80) 80 (40 160) <0.001*
Diuretic dose on day of discharge in IV furosemide equivalents, mg 40 (0,80) 40 (0,80) 80 (0,160) <0.001*
Laboratory findings at discharge
Sodium, mEq/L 138.94.28 139.04.19 136.84.82 <0.001*
Potassium, mEq/L 4.110.51 4.130.50 3.970.53 <0.001*
Chloride, mEq/L 100.65.52 101.15.18 95.06.43 <0.001*
Creatinine, mg/dL 1.531.22 1.461.17 2.341.50 <0.001*
eGFR, mL/min per 1.73 m2 56.028.3 57.528.2 38.125.1 <0.001*
Hemoglobin, g/dL 10.92.0 11.02.0 10.62.0 <0.001*
Median change in laboratory values (discharge—baseline)
Sodium, mEq/L 0 (2.0, 3.0) 0 (2.0, 3.0) 1 (3.0, 3.0) <0.001*
Potassium, mEq/L 0.2 (0.6, 0.3) 0.2 (0.6, 0.3) 0.3 (0.8, 0.25) <0.001*
Chloride, mEq/L 0 (3.0, 3.0) 0 (3.0, 3.0) 3.0 (8.0, 1.0) <0.001*
Creatinine, mg/dL 0 (0.2, 0.1) 0 (0.2, 0.1) 0.1 (0.2, 0.5) <0.001*
eGFR, mL/min per 1.73 m2 0 (5.1, 10) 0.9 (4.8, 11) 2.0 (8.8, 3.8) <0.001*
Hemoglobin, g/dL 0.5 (1.4, 0.20) 0.6 (1.4, 0.1) 0.40 (1.2, 0.3) <0.001*
Outcomes at discharge
Hyponatremia, % 13.5 12.3 28.0 <0.001*
Hypokalemia, % 7.25 6.55 15.7 <0.001*
WRF, % 14.6 13.2 32.3 <0.001*
Length of stay, days 9.2912.4 8.8812.0 14.415.3 <0.001*
Values reported are meanSD, median (quartile 1 to quartile 3), and percentile. WRF was deﬁned by a ≥20% decrease in eGFR from admission to discharge. eGFR indicates estimated
glomerular ﬁltration rate; IV, intravenous; WRF, worsening renal function.
*Signiﬁcant P-value.
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Multivariable models of these outcomes were adjusted for the
metolazone propensity score, the peak loop diuretic dose
received, baseline characteristics and length of stay. We
subsequently determined whether the relationship between
metolazone and increased mortality was mediated by a
number of these outcomes/side effects. First we constructed
separate time-varying Cox proportional hazard models for
hyponatremia, hypokalemia, and WRF to quantify their
relationship with mortality. We then examined the effect of
the addition of these 3 outcomes (potential mediators) on the
magnitude of the hazard ratio for metolazone in the multi-
record Cox proportional hazard model adjusted for the
metolazone propensity score and peak loop diuretic dose.
Finally, to examine the relationships between HDLD use and
mortality, we constructed time-varying Cox proportional
hazards models in a similar fashion to those built for
metolazone except adjusted for the HDLD propensity score.
We further examined the effect of hyponatremia, hypokale-
mia, and WRF on the relationship between HDLDs and
mortality. Statistical analyses were performed using Stata
14.0 (Statacorp, College Station, TX), and statistical signiﬁ-
cance was deﬁned as a 2-sided P<0.05.
Results
Overall, 13 898 admissions in 8908 unique patients met the
inclusion criteria. Baseline characteristics of all admissions
and those with and without metolazone use are presented in
Table 1. In total, 7.5% of all admissions (n=1048) used
metolazone in addition to loop diuretics for diuresis. Patients
who received metolazone exhibited a number of differences in
their presenting characteristics including a greater likelihood
of having received metolazone on a prior admission (Table 1).
In-hospital and treatment-related outcomes of all admis-
sions stratiﬁed by metolazone use are presented in Table 2.
Loop diuretic requirement both during the hospitalization and
at discharge was signiﬁcantly greater in patients also on
metolazone, with a median peak intravenous diuretic dose of
120 mg. However, there was signiﬁcant heterogeneity in the
peak dose of loop diuretic, particularly in those who also were
on metolazone, with some patients receiving only minimal
doses of loop diuretics in conjunction with metolazone and
others on HDLD therapy (Figure 1). On average, patients who
received metolazone during their ADHF hospitalization were
discharged with lower sodium, potassium and chloride levels
as well as lower eGFRs (Table 2). Although patients who
received metolazone were more likely to present with
electrolyte disturbances and worse renal function (Table 1),
the differences at discharge were not merely a reﬂection of
how patients presented, as the median decreases in these
electrolytes were also far more pronounced in the metolazone
group (Table 2). Admissions using metolazone were also
characterized by more hyponatremia, hypokalemia, and WRF
at discharge.
The multivariable model used to determine the propensity
score representing the probability of receiving metolazone is
presented in Table S1. There was good discrimination
between patients who did and did not receive metolazone
as evidenced by the area under the receiver operating curve
of 0.83 (95% conﬁdence interval [CI] 0.82–0.84). Not
surprisingly, 2 of the strongest predictors of metolazone use
were the initial dose of IV diuretic in the hospital and prior
metolazone use. Older age and worse renal function were also
strongly predictive of receiving metolazone (Table S1). The
propensity score successfully adjusted for important covari-
ates, including age, Elixhauser comorbidity index, hemoglobin,
sodium, creatinine, and baseline diuretic dose, as evidenced
by similar values of these covariates across deciles of the
propensity score for metolazone use (Figure 2).
Metolazone and Risk of In-Hospital Adverse
Events
Both the unadjusted and propensity adjusted analyses of
metolazone use and outcomes both during the hospitalization
and at discharge are presented in Figure 3 and Table S2.
Metolazone was strongly and signiﬁcantly associated with its
previously reported side effects: hyponatremia (both incident
























Peak Diuretic Dose in IV Furosemide Equivalents (mg)
Figure 1. The distribution of peak diuretic dose during admis-
sions with and without use of metolazone. Peak diuretic dose was
deﬁned as the highest single intravenous dose of diuretic during
the ﬁrst 7 days of the hospitalization in intravenous furosemide
equivalents. IV indicates intravenous.
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WRF (both any and at discharge). Following adjustment for the
propensity to receive metolazone and peak loop diuretic dose,
the association between metolazone and hyponatremia,
hypokalemia, and WRF remained with minimal attenuation
(Figure 3, Table S2). Furthermore, additional extensive adjust-
ment for baseline characteristics in addition to the metola-
zone propensity score and peak loop diuretic dose only served
to strengthen the signiﬁcant associations between metola-
zone and these outcomes at discharge (Figure 3, Table S2).
Metolazone and Risk of All-Cause Mortality
Over a median follow-up of 423 days from a subject’s ﬁrst
admission, 31.7% of the population died (n=2827). Metola-
zone use was signiﬁcantly associated with increased mortality
(hazard ratio [HR]=1.61; 95% CI 1.42–1.83, P<0.001, Fig-
ure 3). Following adjustment for the metolazone propensity
score and peak diuretic dose, thereby approximating a quasi-
randomized experiment, metolazone remained independently














































































































Deciles of Propensity Score
No Metolazone
Metolazone
Figure 2. Patients were stratiﬁed into deciles of the propensity score and within each decile, patients
who received metolazone were compared with those who did not. The 6 variables shown represent a
combination of important confounders and disease severity indicators. Selection bias was signiﬁcantly
minimized with implementation of the propensity score as shown above. Eq indicates equivalents; IV
intravenous.
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and highly signiﬁcantly associated with mortality (HR=1.24;
95% CI 1.07–1.44, P=0.004; Figure 3). Extensive adjustment
for baseline characteristics and length of stay did not alter the
strong and independent relationship between metolazone and
decreased survival, convincingly supporting a potential causal
link between metolazone and mortality. We then examined if
the effect on all-cause mortality of metolazone was mediated
through the adverse in-hospital outcomes that were strongly
and independently linked. Further adjustment of the survival
model for the 3 putative adverse effects of metolazone (WRF,
hypokalemia, and hyponatremia) resulted in a substantial
decrease in the strength of the HR for metolazone, consistent
with much of the adverse survival effect of metolazone being
mediated through these short-term outcomes (HR=1.06; 95%
CI 0.91–1.23, P=0.448).
High-Dose Loop Diuretics and Adverse Outcomes
Using a similar approach, we next examined the impact of
high doses of loop diuretics on outcomes in our cohort
adjusting for the propensity to receive HDLDs. This propensity
score also demonstrated good discrimination between
patients who did and did not receive HDLDs as evidenced
by the area under the receiver operating curve of 0.92 (95% CI
0.91–0.93). Similar to metolazone, increasing doses of loop
diuretic were signiﬁcantly associated with hyponatremia,
hypokalemia, and WRF (Figure 3, Table S2). Following adjust-
ment for the propensity score, the relationship between
higher doses of loop diuretics and both hyponatremia and
hypokalemia as well as incident hyponatremia and incident
hypokalemia dramatically attenuated (Figure 3, Table S2). The
relationship between HDLDs and WRF was strong and
minimally attenuated after adjustment regardless of whether
WRF occurred during the hospitalization or only at time of
discharge.
Higher loop diuretic dose demonstrated a strong univariate
association with increased mortality (HR=1.15 per 100 mg of
IV furosemide, 95% CI 1.08–1.23, P<0.001; Figure 3).
Following adjustment for the propensity score, there was no
signiﬁcant relationship between the higher peak inpatient
diuretic dose and survival (HR=0.99 per 100 mg of IV
furosemide, 95% CI 0.91–1.08, P=0.82; Figure 3). However,
with extensive adjustment for baseline characteristics as well
as potential mediators of adverse outcomes (hyponatremia,
hypokalemia, and WRF), increasing doses of loop diuretics
demonstrated a trend toward improved survival (HR=0.93 per
100 mg of IV furosemide, 95% CI 0.85–1.006, P=0.07).
Metolazone Use in Patients on High-Dose Loop
Diuretics
Given the heterogeneity in dose of loop diuretic used in
conjunction with adjuvant thiazide, as an exploratory analysis,
we examined the relationship between metolazone, its
mediators and mortality in only those patients on high-dose
loop diuretics (>160 mg intravenous furosemide equivalents;
n=469). Remarkably, amongst patients receiving HDLDs (of
which 51% received metolazone) there was no relationship
with mortality even in the unadjusted analysis (HR=1.10, 95%
CI 0.73–1.39; P=0.95). The lack of an association between
metolazone and mortality persisted following adjustment for
the metolazone propensity score, baseline characteristics,
and potential mediators of the adverse effect of metolazone
(WRF, hypokalemia, and hyponatremia), with the point esti-
mate now favoring a protective effect, although this was not
signiﬁcant. (HR=0.73, 95% CI 0.50–1.08, P=0.11).
Discussion
The principal ﬁnding of this study is that in a large and diverse
real-world population, using statistical methodology to reduce
the inﬂuence of confounding by indication, adjuvant metola-
zone use during ADHF was independently and strongly
associated with hyponatremia, hypokalemia, WRF, and
decreased long-term survival. This risk associated with
metolazone appeared to be largely mediated through these
in-hospital acute adverse events. However, when the use of
HDLDs were subjected to the same analytic methodology,
there was no risk for hyponatremia, hypokalemia, or mortality.
Figure 3. The unadjusted, propensity adjusted, and propensity plus multivariable adjusted relationships between metolazone use and
hyponatremia, hypokalemia, worsening renal function (WRF), and all-cause mortality as well as the relationships between increasing doses of
loop diuretic are presented above. All metolazone propensity-adjusted analyses are also adjusted for peak-loop diuretic dose received in the
hospital in intravenous furosemide equivalents as a representation of loop diuretic requirement. Multivariable models included adjustment for
age at encounter, race, sex, arrhythmia, valvular disease, pulmonary circulatory disease, hypertension with and without complications, chronic
obstructive pulmonary disease, diabetesmellitus with and without complications, hypothyroidism, renal failure, electrolyte disease, neurologic
disease, paralysis, liver disease, lymphoma, malignancy with and without metastasis, rheumatologic disease, coagulopathy, obesity, anemia
secondary to blood loss, drug abuse, Elixhauser comorbidity index, prior metolazone use, readmission, as well as baseline laboratory values
including sodium, chloride, bicarbonate, blood urea nitrogen, white blood cell count, hemoglobin, platelets, glomerular ﬁltration rate and length
of stay. WRFwas deﬁned as a ≥20% decrease in estimated glomerular ﬁltration rate from admission to discharge. Hyponatremia was deﬁned as
a sodium level <135 mEq/L and hypokalemia was deﬁned as a serum potassium <3.5 mEq/L. All hazard ratios reported for furosemide are for
every 100 mg of intravenous furosemide. MV indicates multivariable; WRF, worsening renal function.
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In light of the existing randomized trial data to support the
safety of aggressive loop diuretic dosing,23 and the currently
presented ﬁndings suggesting a mortality disadvantage with
metolazone as well as an increased risk of electrolyte
disturbances and WRF, routine escalation of loop diuretic
doses may be the preferred approach for the management of
ADHF until adequately powered trials are available to more
deﬁnitively inform this question.
The primary treatment for ADHF is intravenous loop
diuretic, and in most patients, this therapy at modest doses
is adequate to improve symptoms.24 However, compen-
satory sodium reabsorption that occurs in the distal
convoluted tubule, the site of action of thiazide diuretics,
is an important cause for diuretic resistance.25 The addition
of a thiazide or thiazide-like diuretic (ie, metolazone) to loop
diuretics, often referred to as sequential nephron blockade,
inhibits compensatory distal tubular sodium reabsorption,
thereby enhancing natriuresis.26 Furthermore, unlike loop
diuretics, thiazides do not directly stimulate renin secretion
at the macula densa and therefore do not activate the renin
angiotensin aldosterone system to the same extent.27
Physiologically this seems like an attractive approach to
decongestion, one that is supported in the current heart
failure practice guidelines, despite no randomized trials
comparing combination diuretic therapy with a thiazide to
loop diuretics alone.4 In fact, most studies examining
metolazone use in HF are small, single-center retrospective
analyses without a control arm, published over 25 years ago,
that focused on end points like urinary volume and sodium
concentration as opposed to clinical outcomes.8,10,28,29
Nevertheless, the cumulative existing evidence in only 350
patients does illustrate that metolazone produces a 3-fold
increase in natriuresis, increases weight loss and improves
diuresis in patients who were previously not suitable for
hospital discharge.7–10,28–30
Of course, these beneﬁts of thiazides do not come without
a cost; by blocking sequential nephron segments, the kidney’s
ability to deploy diuretic breaking and prevent overdiuresis is
impaired.27 As a result, the sequelae of overzealous diuresis
like WRF, as we found here, are to be expected. Furthermore,
because of their location of action, thiazides directly cause
hyponatremia and lead to a disproportionate loss of potas-
sium, thus predisposing to hypokalemia, which affected >30%
of patients in this study who received metolazone.29 As a
result of these mechanisms, thiazides can either beneﬁt
patients by accelerating decongestion in the face of diuretic
resistance or harm patients via electrolyte depletion and WRF.
We are therefore left with clinical equipoise as to whether
thiazides should be used early in ADHF, and if so, when and in
which subset of patients.
This treatment question often presents itself in the setting
of a patient who is not responding to traditional doses of
diuretics with the therapeutic options including increasing
loop diuretics to higher doses versus the addition of a thiazide
diuretic. Although there is a lack of randomized data to
speciﬁcally answer this question, the DOSE (Diuretic Opti-
mization Strategies Evaluation) trial provides support for the
safety and efﬁcacy of intravenous HDLDs. In this 308 ADHF
patient population, patients randomized to intravenous HDLD
received an average of 773 mg of intravenous furosemide in
72 hours and experienced greater ﬂuid and weight loss, a
greater incidence of WRF, but without any worsening in death
or rehospitalization.23 In our study using propensity score
adjustment to reduce confounding by indication, we found
similar ﬁndings with a greater incidence of WRF but no
survival disadvantage. The application of these identical
epidemiologic methods to metolazone revealed a persistent
signiﬁcant mortality disadvantage. Therefore, when faced with
a choice of loop diuretic escalation versus employing a
therapy that may carry a mortality risk mediated by its side
effect proﬁle, our results would suggest the safer therapy may
be the dose escalation of loop diuretics.
That is not to say that there may be situations when the
addition of a thiazide diuretic is appropriate or when the
potential beneﬁts outweigh the known risks as shown in this
study. Patients on the highest doses of diuretic therapy in this
study who went on to receive metolazone did not appear to
suffer the same mortality disadvantage. To the contrary, when
the analysis was adjusted for the mediators of metolazone’s
mortality impact, there was a trend toward a beneﬁt of
metolazone. Although this subgroup analysis was highly
exploratory and should be interpreted as hypothesis-generat-
ing only, it does call for further investigation into which
patients may in fact beneﬁt from combination diuretic
therapy.
Limitations
There are limitations that must be considered when inter-
preting these results. First, although propensity score adjust-
ment signiﬁcantly reduces confounding and was developed to
simulate a quasi-randomized study design for the purposes of
causal inference, this study was not a randomized controlled
trial and uncontrolled confounding most likely remains.
Although we have adjusted our analysis more expansively
than prior published reports, bias may still occur as the
propensity score cannot adjust for unmeasured confounders.
Furthermore, given the retrospective nature of this study,
causality is impossible to demonstrate. Secondly, physicians
were not masked to electrolytes or measures of renal function
and may have altered treatment decisions in response to
these data. Still, our focus was on the presence of known side
effects of metolazone at discharge, so regardless of physician
treatment decisions, the physician in charge of the patient
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still felt despite the presence of electrolyte abnormalities or
WRF that the patient was suitable for discharge. Third,
although our data were generated from both academic and
community hospital environments, all hospitals were located
in the same state and health system, potentially limiting the
generalizability of the results. Fourth, given the similarities of
this data set to claims data, we lacked access to all granular
data and clinical information within an individual patient’s
chart that could signiﬁcantly affect mortality like blood
pressure, ejection fraction and ﬂuid and weight loss. We
relied on diagnostic codes incorporated in the Elixhauser
Comorbidity Index which has been validated in congestive
heart failure.31 Finally, as this analysis was restricted to
metolazone, these results may not be generalizable to all
thiazide diuretics. As a result of the above limitations, our
ﬁndings serve to primarily initiate further investigation into
combination diuretic therapy with metolazone.
Conclusions
During the treatment of ADHF, metolazone use is indepen-
dently associated with increased mortality. This survival
disadvantage appears to be mediated predominantly by the
hyponatremia, hypokalemia, and WRF metolazone induces.
Importantly, treatment of ADHF with high doses of loop
diuretics, a clinical alternative to the addition of a thiazide
diuretic, demonstrates no survival disadvantage. These data
suggest combination diuretic therapy with metolazone is not
without risk and may not be appropriate in all patients.
Further research is necessary to establish which patients, are
most likely to beneﬁt from combination diuretic therapy. Until
these data are available, based on the current ﬁndings in the
context of prior published studies, maximizing loop diuretic
dose, rather than early introduction of adjuvant metolazone,
may be the preferred strategy in clinical practice.
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Table S1. Multivariable model of metolazone use utilized for propensity score determination. 
Covariate OR (95% CI) P (Wald) 
First dose of diuretic on admission in intravenous furosemide equivalents (per mg) 1.01 (1.007-1.01) <0.001 
Age at encounter (per year) 0.97 (0.96-0.98) <0.001 
Prior metolazone 3.01 (2.38-3.80) <0.001 
Blood urea nitrogen (mg/dL) 1.01 (1.009-1.02) <0.001 
Saint Raphael Campus vs. Yale New Haven Hospital 0.55 (0.46-0.65) <0.001 
Bridgeport Hospital vs. Yale New Haven Hospital 0.67 (0.54-0.83) <0.001 
Arrhythmia 1.85 (1.53-2.25) <0.001 
Fluid and electrolyte disorders 1.72 (1.43-2.07) <0.001 
Creatinine (mg/dL) 0.86 (0.81-0.93) <0.001 
Valvular disease 1.44 (1.20-1.73) <0.001 
Pulmonary circulatory disease 1.52 (1.23-1.88) <0.001 
Chloride (mEq/L) 0.96 (0.93-0.98) <0.001 
eGFR (ml/min/1.73m2) 0.99 (0.986-0.996) <0.001 
Obesity 1.41 (1.16-1.71) 0.001 
Hemoglobin (g/dL) 0.95 (0.92-0.98) 0.002 
Drug abuse 0.58 (0.38-0.88) 0.011 
Sodium (mEq/L) 1.03 (1.01-1.06) 0.011 
Male sex 1.20 (1.03-1.40) 0.017 
Diabetes with complications 1.33 (1.20-1.68) 0.019 
Renal failure 1.48 (1.07-2.05) 0.019 
White blood cell count 0.98 (0.97-0.998) 0.026 
Anemia secondary to blood loss 0.54 (0.29-1.01) 0.055 
Paralysis 0.35 (0.12-1.02) 0.055 
Hypertension without complications 0.79 (0.62-1.02) 0.068 
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Lymphoma 1.41 (0.91-2.18) 0.120 
Diabetes without complications 1.16 (0.96-1.40) 0.125 
Liver disease 1.22 (0.93-1.61) 0.150 
COPD 0.87 (0.71-1.07) 0.192 
Rheumatologic disease 0.80 (0.55-1.17) 0.257 
Solid tumor without metastasis 0.78 (0.53-1.20) 0.277 
Neurologic disease 0.85 (0.64-1.15) 0.307 
Hypothyroidism 1.10 (0.90-1.35) 0.339 
Elixhauser comorbidity index 0.96 (0.87-1.06) 0.282 
Bicarbonate (mEq/L) 1.01 (0.99-1.03) 0.446 
Coagulopathy 1.11 (0.83-1.49) 0.469 
Metastatic cancer 0.83 (0.45-1.53) 0.549 
Hypertension with complications 0.98 (0.73-1.33) 0.910 
Readmission 0.99 (0.85-1.17) 0.940 
AUC: 0.8312 
 
Covariates presented in order of strongest to weakest predictors as determined by the absolute value of the z-score. 
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Table S2. Relationships between metolazone and loop diuretic use with incident hyponatremia, 
incident hypokalemia and any WRF during heart failure hospitalization. 
Outcome 
Metolazone Hazard 
Ratio (95% CI) 





   Univariate 2.50 (1.99-3.15) <0.001 1.46 (1.30-1.63) <0.001 
   Propensity Adjusted 2.23 (1.75-2.84) <0.001 1.20 (1.05-1.38) 0.008 
   Propensity and MV Adjusted 2.06 (1.59-2.66) <0.001 1.14 (0.97-1.34) 0.109 
     
New Hypokalemia 
   Univariate 2.96 (2.36-3.70) <0.001 1.16 (1.03-1.32) 0.017 
   Propensity Adjusted 2.94 (2.34-3.69) <0.001 0.96 (0.82-1.12) 0.580 
   Propensity and MV Adjusted 2.99 (2.34-3.81) <0.001 0.96 (0.82-1.14) 0.672 
     
Any WRF 
   Univariate 2.31 (2.00-2.67) <0.001 1.28 (1.19-1.37) <0.001 
   Propensity Adjusted 2.50 (2.15-2.90) <0.001 1.25 (1.16-1.35) <0.001 
   Propensity and MV Adjusted 2.54 (2.17-2.97) <0.001 1.23 (1.13-1.35) <0.001 
The unadjusted, propensity adjusted and propensity plus multivariable adjusted relationships between 
metolazone use and incident hyponatremia, incident hypokalemia, and any worsening renal function 
(WRF) as well as the relationships between increasing doses of loop diuretic are presented above.  All 
metolazone propensity-adjusted analyses are also adjusted for peak loop diuretic dose received in the 
hospital in intravenous furosemide equivalents as a representation of loop diuretic requirement.  
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pulmonary circulatory disease, hypertension with and without complications, chronic obstructive 
pulmonary disease, diabetes with and without complications, hypothyroidism, renal failure, electrolyte 
disease, neurologic disease, paralysis, liver disease, lymphoma, malignancy with and without metastasis, 
rheumatologic disease, coagulopathy, obesity, anemia secondary to blood loss, drug abuse, Elixhauser 
comorbidity index, prior metolazone use, readmission, as well as baseline laboratory values including 
sodium, chloride, bicarbonate, blood urea nitrogen, white blood cell count, hemoglobin, platelets, 
glomerular filtration rate and length of stay. Any WRF was defined as a ≥ 20% decrease in estimated 
glomerular filtration rate from admission to the point of worst eGFR during the hospitalization. New 
hyponatremia was defined as a sodium level < 135 mEq/L and new hypokalemia was defined as a serum 
potassium <3.5 mEq/L that developed during the course of the hospitalization (i.e. patients with new 
electrolyte abnormalities did not meet these criteria at admission).  All hazard ratios reported for 
furosemide are for every 100 mg of intravenous furosemide. MV: multivariable     
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